Загрузка...

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II trial testing the efficacy of intermediate dose rabbit anti-thymocyte globulin (Thymoglobulin Thymo) in...

Полное описание

Сохранить в:

Библиографические подробности
Опубликовано в: :	Bone Marrow Transplant
Главные авторы:	Al-Kadhimi, Z, Gul, Z, Abidi, M, Lum, LG, Deol, A, Chen, W, Jang, H, Ozust, C, Langston, A, Waller, E, Uberti, J
Формат:	Artigo
Язык:	Inglês
Опубликовано:	2017
Предметы:	Article
Online-ссылка:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6857176/ https://ncbi.nlm.nih.gov/pubmed/28581472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2017.95
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

Схожие документы